Abstract
Doxorubicin-driven cardiotoxicity could result in dilated cardiomyopathy and heart failure (HF). Previously, we showed that periplocymarin exerted a cardiotonic role by promoting calcium influx and attenuating myocardial fibrosis induced by isoproterenol (ISO) by improving the metabolism of cardiomyocytes. However, the impact of periplocymarin on doxorubicin (DOX)-triggered cardiomyopathy has not been investigated. In the current study, C57BL/6 mice were randomly divided into three groups, namely, the control, DOX, and DOX+periplocymarin groups. The cardiac function and apoptosis were measured. Our results revealed that periplocymarin administration greatly improved the DOX-induced cardiac dysfunction manifested by the ejection fraction (EF%), fractional shortening (FS%), left ventricular posterior wall thickness (LVPW), left ventricular anterior wall thickness (LVAW), left ventricular (LV) mass, and attenuated DOX-induced cardiomyocyte apoptosis assessed by hematoxylin and eosin (H&E) staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, and western blotting. Further study using H9c2 cells revealed that the pretreatment of periplocymarin suppressed DOX-induced apoptosis evidenced by annexin V staining. Moreover, liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis demonstrated that DOX lead to an accumulation in serum ceramide, and the pre-treatment of periplocymarin could reverse this phenomenon. Network pharmacology also demonstrated that ceramide metabolism was involved in the process. Consistently, real-time PCR showed that periplocymarin significantly abolished the induction of the genes involved in the de novo synthesis of ceramide, i.e., CerS2, CerS4, CerS5, and CerS6, and the induction was attributed to the treatment of DOX. Collectively, these results suggested that periplocymarin reduced cardiomyocyte apoptosis to protect hearts from DOX-induced cardiotoxicity and the de novo synthesis of ceramides was involved in this process.
Highlights
Doxorubicin (DOX) has been approved for the treatment of diverse cancers involving leukemia, neuroblastoma, and breast cancer [1]
We demonstrated that the administration of periplocymarin improved DOX-induced heart failure (HF) in mice, and we uncovered that periplocymarin ameliorated cardiomyocytes apoptosis and suppressed ceramides production induced by DOX both in vivo and in vitro
Periplocymarin treatment successfully rescued the decrease in EF% and FS% triggered by DOX (Figures 1B,C)
Summary
Doxorubicin (DOX) has been approved for the treatment of diverse cancers involving leukemia, neuroblastoma, and breast cancer [1]. It has been reported that the dose-dependent cardiotoxicity of DOX often results in cardiac systolic dysfunction and leads to heart failure (HF). This potential risk greatly restricted the clinical application of DOX. Developing effective therapeutic drugs or targets that are capable of combatting cardiomyocytes apoptosis triggered by DOX is greatly warranted. Periplocymarin prevents isoproterenol (ISO)induced cardiac fibrosis via improving the cardiomyocyte metabolism by targeting endothelial nitric oxide synthase (eNOS) and cyclooxygenase-2 (COX-2) [16]. We demonstrated that the administration of periplocymarin improved DOX-induced HF in mice, and we uncovered that periplocymarin ameliorated cardiomyocytes apoptosis and suppressed ceramides production induced by DOX both in vivo and in vitro
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
